Overview

Gender

male

Muhammad joined Autolus from the Burnham Institute in La Jolla, California, an NIH-designated cancer centre, where he was the vice president of drug discovery and translational medicine leading the institute’s drug discovery portfolio and its early development. Prior to this, he was a senior director of biology and translational medicine at GlaxoSmithKline where he led oncology R&D teams developing biologic and small molecule therapeutics from target ID through clinical candidate selection and early development in the cancer biology areas of signalling pathways, cancer stem cells, antibody drug conjugates and immuno-oncology leading to programs progression into early and mid-stage clinical trials.


Prior to GSK, he was the group leader in oncology translational medicine at MedImmune where he led an R&D team developing antibody therapeutics. Muhammad started his industry career as a lab head at Novartis oncology in Cambridge Massachusetts. He received a doctoral degree in molecular genetics cloning and characterizing DNA repair genes, and completed a postdoctoral fellowship in cancer and stem cell biology at the University of Michigan Medical School. Mo did his undergraduate studies (BS) in mathematics and biology at the American U of Beirut.